Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 Investing Pro 0
💎 Reveal Undervalued Stocks Hiding in Any Market Get Started
Close

Bluebird bio Inc (BLUE)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Bluebird's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
4.43 +0.08    +1.84%
24/03 - Closed. Currency in USD ( Disclaimer )
After Hours
4.50
+0.07
+1.58%
19:37:09 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 3,220,205
  • Bid/Ask: 4.40 / 4.50
  • Day's Range: 4.20 - 4.45
Bluebird 4.43 +0.08 +1.84%

BLUE Balance Sheet

 
Featured here, the Balance Sheet for Bluebird bio Inc, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Collapse All
Period Ending: 2022
30/09
 2022
30/06
 2022
31/03
 2021
31/12
Total Current Assets 160.44 167.46 254.92 336.52
Cash and Short Term Investments 139.63 132.51 211.59 299.5
Cash - - - -
Cash & Equivalents 66.48 81.5 106.26 161.16
Short Term Investments 73.16 51.01 105.33 138.34
Total Receivables, Net 10.97 8.84 9.71 9.11
Accounts Receivables - Trade, Net 10.97 8.84 9.71 9.11
Total Inventory - - - -
Prepaid Expenses 8.27 24.47 31.8 25.63
Other Current Assets, Total 1.56 1.64 1.82 2.28
Total Assets 520.1 573.59 491.07 593.8
Property/Plant/Equipment, Total - Net 300.22 307.3 123.13 101.24
Property/Plant/Equipment, Total - Gross 323.79 329.8 144.34 121.64
Accumulated Depreciation, Total -23.57 -22.5 -21.21 -20.41
Goodwill, Net 5.65 5.65 5.65 5.65
Intangibles, Net - - - -
Long Term Investments 1.41 40.64 55.05 97.11
Note Receivable - Long Term - - - -
Other Long Term Assets, Total 52.39 52.55 52.33 53.28
Other Assets, Total 63.75 43.8 97.44 131.52
Total Current Liabilities 126.73 148.86 142.89 152.99
Accounts Payable 18.62 24.86 28.35 25.88
Payable/Accrued - - - -
Accrued Expenses 61.21 72.24 85.97 100.52
Notes Payable/Short Term Debt - - - -
Current Port. of LT Debt/Capital Leases 43.79 48.45 25.51 23.15
Other Current liabilities, Total 3.1 3.3 3.06 3.43
Total Liabilities 361.24 393.48 227.81 219.52
Total Long Term Debt - - - -
Long Term Debt - - - -
Capital Lease Obligations - - - -
Deferred Income Tax - - - -
Minority Interest - - - -
Other Liabilities, Total 234.51 244.62 84.92 66.52
Total Equity 158.86 180.12 263.26 374.28
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 0.829 0.735 0.714 0.711
Additional Paid-In Capital 4181.39 4126.01 4109.08 4096.4
Retained Earnings (Accumulated Deficit) -4018.74 -3942.22 -3842.08 -3719.92
Treasury Stock - Common - - - -
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total -4.63 -4.42 -4.46 -2.91
Total Liabilities & Shareholders' Equity 520.1 573.59 491.07 593.8
Total Common Shares Outstanding 82.88 73.55 71.44 71.12
Total Preferred Shares Outstanding - - - -
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

BLUE Comments

Write your thoughts about Bluebird bio Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Giancarlo Grosso
Giancarlo Grosso Oct 04, 2022 1:44AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Real Endpoints Marketplace announces collaboration with bluebird bio to help scale delivery of a first-of-its-kind value-based contract for one-time gene therapy - GlobeNewswireReal Endpoints, the leading market-access platform and advisory firm, announced a collaboration with bluebird bio, inc., to provide multiple health plans with access to an innovative,
Reply
2 1
Report
Johny Cash
Johny Cash Jul 31, 2022 3:46PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
will it go up?
Reply
2 0
Report
Theodore Striker
Theodore Striker Jul 31, 2022 3:46PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
yes
Reply
1 0
Report
Gaetano Ciancaglini
Gattomao Dec 21, 2021 10:00AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Slite brease...finally going UP like a Kite!!!
Reply
2 0
Report
Ra Pa
Ra Pa Nov 08, 2021 10:14AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
falling like a little stone down a chasm
Reply
0 0
Report
Bm Bendary
Bm Bendary Nov 05, 2021 9:42AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
The stock appears here at Investing.com gaining .2% at 16.4 usd?
Reply
1 0
Report
Bm Bendary
Bm Bendary Nov 05, 2021 9:42AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
As if yesterday closing was 16:30!
Reply
0 0
Report
Ra Pa
Ra Pa Nov 05, 2021 7:54AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Why so much down again?
Reply
0 0
Report
John Brand
John Brand Nov 05, 2021 7:54AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
TSVT tax-free dividend distribution
Reply
1 0
Report
Ra Pa
Ra Pa Nov 05, 2021 7:54AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
ok thanks, any value left on this or should we sell the old stock?
Reply
0 0
Report
Eduardo Camillo
Eduardo Camillo Oct 23, 2021 3:41PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Dear bluebird bio, Inc. Stockholder:In January 2021, we announced a transformative milestone for bluebird bio, Inc.—our intent to separate our oncology portfolio and programs from our severe genetic disease portfolio and programs, thereby creating two independent, publicly traded companies. The strategic objectives of the separation are to unlock value, enhance operational performance and strategic flexibility and tailor the capital structures to best serve these distinct businesses.We believe the best way to realize the full potential of this separation is for bluebird bio, Inc. and 2seventy bio, Inc. to operate independently, with distinct management teams and boards of directors dedicated to their unique business strategies. Through this separation, we have the potential to create two focused, durable businesses that are well-positioned with the resources, talent and foundation to be industry leaders in their respective fields.Going forward, bluebird bio, Inc. intends to focus primarily on its programs in severe genetic disease, including betibeglogene autotemcel (beti-cel; formerly LentiGlobin gene therapy for β-thalassemia), LentiGlobin gene therapy for sickle cell disease, and elivaldogene autotemcel (eli-cel; formerly Lenti-D gene therapy for cerebral adrenoleukodystrophy). 2seventy bio, Inc. plans to focus primarily on the discovery and development of novel engineered cell therapies for cancer, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. 2seventy bio, Inc. expects to commercialize idecabtagene vicleucel (ide-cel; being commercialized as Abecma) in the United States and develop bb21217 through its collaboration arrangement with Bristol-Myers Squibb.Upon completion of the separation, 2seventy bio, Inc. will be spun out of bluebird bio, Inc. and established as an independent, publicly traded company. The separation is anticipated to be generally tax-free to bluebird bio, Inc. stockholders. Under the terms of the distribution, each bluebird bio, Inc. stockholder will receive one share of 2seventy bio, Inc. common stock for every three shares of bluebird bio, Inc. common stock held of record on October 19, 2021, the record date for the distribution. You do not need to take any action to receive the common stock of 2seventy bio, Inc. to which you are entitled as a bluebird bio, Inc. stockholder as of the record date.Please read the attached information statement, which is being shared with all bluebird bio, Inc. stockholders as of the record date for the distribution. It describes the separation in detail and contains important information about bluebird bio, Inc. and 2seventy bio, Inc.We thank you for your continued support of bluebird bio, Inc. Sincerely,Daniel S. LynchChairman of the Boardbluebird bio, Inc.
Reply
5 0
Report
Eduardo Camillo
Eduardo Camillo Oct 23, 2021 3:41PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Dear Future 2seventy bio, Inc. Stockholder:On behalf of the entire future 2seventy bio, Inc. team, I am pleased to welcome you as a future stockholder of our new company.2seventy bio, Inc. will be a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. Its programs will be based on chimeric antigen receptor (CAR) technology and T cell receptor technology. At launch, 2seventy bio, Inc.’s programs will include idecabtagene vicleucel; ide-cel, or Abecma, and bb21217, CAR-T cell product candidates for the treatment of multiple myeloma, which are partnered under a collaboration arrangement with Bristol-Myers Squibb. We believe our team’s expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies will enable us to develop a pipeline of highly innovative, targeted cellular therapies for patients with cancer.Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol “TSVT” in connection with the distribution of our company’s common stock by bluebird bio, Inc.I invite you to learn more about 2seventy bio, Inc. by reviewing the enclosed information statement. We look forward to our future as an independent company, and to your support as a 2seventy bio, Inc. stockholder as we begin this new and exciting chapter.Sincerely,Nick LeschlyChief Executive Officer2seventy bio, Inc.
Reply
1 0
Report
Thierry Maa
Thierry Maa Aug 16, 2021 10:35AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Falling knife
Reply
0 0
Report
игорь рудов
игорь рудов Aug 10, 2021 12:08AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I believe that shareholders and the board of directors should force Nick Leschly to leave. he is not able to manage the company well and make it profitable. this will be well received by investors. this is now one of his few steps that will make the price rise.
Reply
4 1
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email